Treatment with Esperoct (turoctocog alfa pegol) effectively prevents bleeding during and after major surgery in patients with severe hemophilia A, final data from a Phase 3 trial show. The study, “…
Search results for:
A summary could not be generated for your search query. Here are some search results.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Dr. Reddy’s Laboratories announced the U.S. launch of a generic version of DDAVP (desmopressin acetate), used to control bleeding in people with mild hemophilia A. The generic is available under the name Desmopressin Acetate Injection USP, 4 micrograms/mL, in a carton of 10 single-dose ampules…
Obesity increases the frequency of joint bleeds and degree of pain, and lowers overall life quality of people with hemophilia in the United States, most healthcare providers agreed in an online survey. But a sizable number, about 40%, did not discuss weight with patients during care…
Catalyst Biosciences has received a European Union patent for its investigational hemophilia B treatments, including its lead therapy candidate, dalcinonacog alfa (DalcA) and a preclinical gene therapy candidate called CB…
SCT800, a replacement therapy containing a man-made form of clotting factor VIII (FVIII), appears to be safe and effective at treating and preventing bleeds in adolescents and adults with severe hemophilia A, a study has found. The study, “Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted…
https://www.youtube.com/watch?v=pTIVORH7anc This video from Wochit News is all about a new treatment for severe hemophilia A. The Children’s Hospital of Los Angeles, California, has developed a breakthrough treatment that can reduce the bleeding episodes in people living with hemophilia A by up to 90 percent. MORE: Emicizumab shows…
Hemophilia A is a rare genetic disorder that affects the blood’s ability to clot properly. It is the most common form of hemophilia, responsible for 80% of all cases.
While hemophilia A and hemophilia B are both bleeding disorders characterized by deficiencies in blood clotting factors, there are differences in one type versus the other, particularly in the specific genetic mutations that cause the disease, and in some of the treatment methods.